Phase 3 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and sign a consent form agreeing to take part in the study.
• People aged between 18 and 75 years old (inclusive).
• People whose general physical functioning falls within an acceptable range, as measured by a standard medical scoring system (a score of 0, 1, or 2 on the ECOG scale — confirm with trial site).
• People with an expected survival of at least 3 months.
• People who have a confirmed diagnosis of multiple myeloma with disease that can be measured and tracked during the trial.
• People who have already had at least one previous treatment for multiple myeloma, which must have included both lenalidomide and a specific type of drug called a proteasome inhibitor (such as bortezomib, carfilzomib, or ixazomib), either separately or together.
• People whose multiple myeloma has shown signs of getting worse during or after their most recent treatment.
• People whose liver, kidneys, heart, and other vital organs are functioning at an adequate level.
• Women who could become pregnant must agree to use contraception for 4 weeks before starting the trial, throughout the trial, and for 6 months after stopping the study drug SG301 or 4 weeks after stopping pomalidomide (whichever is longer), and must have two negative pregnancy tests before starting treatment.

Who may not be able to join:

• People whose multiple myeloma never responded to any treatment at all (called "primary refractory" disease).
• People whose myeloma has spread outside the bone marrow in a way that is not connected to the bone (confirm with trial site).
• People whose myeloma did not respond to a previous treatment involving a type of drug called a CD38 monoclonal antibody (such as daratumumab).
• People who have previously been treated with a drug called pomalidomide.
• People who have received standard chemotherapy or certain targeted cancer medicines within 2 weeks (or within 5 half-lives of that drug, whichever comes first) before starting the trial.
• People who have received biological cancer therapies within 4 weeks (or within 5 half-lives of that drug, whichever comes first) before starting the trial.
• People who have taken part in another clinical trial and received an experimental treatment within 4 weeks (or within 5 half-lives, whichever comes first, but no less than 14 days) before starting this trial.
• People with active hepatitis B or hepatitis C infection.
• People with a known HIV infection.
• People with active tuberculosis or a positive blood test for syphilis.
• People with significant problems affecting major organs that do not meet the trial's health requirements.
• People who have previously had a stem cell transplant (either from a donor or using their own cells) before joining the trial.
• People with a known allergy to any ingredient in the study medicines.
• People with other significant medical or mental health conditions — such as uncontrolled infections, uncontrolled diabetes, or certain lung conditions — that could interfere with the trial or pose a risk to their safety.

Important: Always verify eligibility with the trial site directly before applying.